wp-plugin-hostgator
domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init
action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home4/scienrds/scienceandnerds/wp-includes/functions.php on line 6114ol-scrapes
domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init
action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home4/scienrds/scienceandnerds/wp-includes/functions.php on line 6114Source: https:\/\/www.theverge.com\/2022\/7\/13\/23158596\/novavax-covid-vaccine-fda-authorize-protein<\/a> The Food and Drug Administration authorized<\/a> the Novavax COVID-19 vaccine for people 18 and older, the fourth shot cleared in the United States. It\u2019s been a long road for this vaccine, and the company faced multiple setbacks over the past few years. <\/p>\n It\u2019s a different type of vaccine than the ones already on the market in the US \u2014 it\u2019s a protein-based vaccine that delivers pieces of the virus spike protein directly to the body. Clinical trials found that the shot was 90 percent effective<\/a> at preventing COVID-19. The trials, though, were conducted in early 2021 \u2014 before the delta and then omicron variants of the virus took over, so those numbers would likely be lower now. <\/p>\n Early on<\/a> in the pandemic, experts thought that the Novavax vaccine was one of the best bets against the coronavirus. The US government invested $1.6 billion<\/a> in Novavax\u2019s efforts, more than any other company at the time. But the company had never brought a vaccine to market. It had issues with its manufacturing<\/a>, and it didn\u2019t start testing its vaccine until well after US frontrunners <\/strong>Moderna and Pfizer \/ BioNTech. Even after the clinical trial results showed that the shot worked well, the manufacturing issues delayed any submissions<\/a> to the FDA. <\/p>\n FDA leadership hopes that having an alternative to the mRNA vaccines could be a way to encourage people who are still unvaccinated to get a shot. \u201cHaving a protein-based alternative may be more comfortable for some in terms of their acceptance of vaccine,\u201d said Peter Marks, the FDA\u2019s director of the Center for Biologics Evaluation and Research, during a meeting of the agency\u2019s independent expert committee.<\/p>\n<\/div>\n
\n
<\/br><\/code><\/p>\n